Meta-analyses of FibroTest diagnostic value in chronic liver disease
2007

FibroTest's Effectiveness in Diagnosing Liver Fibrosis

Sample size: 6378 publication 10 minutes Evidence: high

Author Information

Author(s): Poynard Thierry, Morra Rachel, Halfon Philippe, Castera Laurent, Ratziu Vlad, Imbert-Bismut Françoise, Naveau Sylvie, Thabut Dominique, Lebrec Didier, Zoulim Fabien, Bourliere Marc, Cacoub Patrice, Messous Djamila, Munteanu Mona, de Ledinghen Victor

Primary Institution: Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, Université Paris VI, CNRS ESA 8067 Paris, France

Hypothesis

The FibroTest diagnostic value is similar across different chronic liver diseases and fibrosis stages.

Conclusion

FibroTest is an effective alternative to biopsy in patients with chronic hepatitis C and B, ALD, and NAFLD.

Supporting Evidence

  • FibroTest was validated in patients with chronic hepatitis C and other liver diseases.
  • The mean standardized AUROC for FibroTest was 0.84.
  • FibroTest diagnostic value is similar for intermediate and extreme fibrosis stages.

Takeaway

FibroTest is a blood test that helps doctors check for liver damage without needing a painful liver biopsy.

Methodology

Two meta-analyses were performed, one combining published studies and another using an integrated database of individual data.

Potential Biases

Few independent studies in other chronic liver diseases may introduce bias.

Limitations

The number of studies and patients in non-HCV related diseases is smaller than those in HCV.

Participant Demographics

The study included 6,378 subjects with chronic liver diseases: 3,501 HCV, 1,457 HBV, 267 NAFLD, 429 ALD, and 724 mixed.

Statistical Information

P-Value

0.001

Confidence Interval

95% CI, 0.83–0.86

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-230X-7-40

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication